Magle Chemoswed

Q3 2021 KEY INDICATORS

• Net sales amounted to 30.2 MSEK (30.4).
• EBITDA equaled 6.5 MSEK (3.5).
• Operating profit (EBIT) is 3.4 MSEK (0.8)
• Profit after tax amounted to 2.9 MSEK (1.0)
• Earnings per share amounted to SEK 0,27 (0,09) per share

RECENT BUSINESS ACCOMPLISHMENTS

• EmboCept® S is approved in the CIRSE European Guidelines
• Commercial order for AXXO Woundgel received
• ISO13485:2016 certification inspection passed
• Magle Chemoswed funds new post-doc position at Copenhagen University

“We continue to execute on our strategy to be a leader in high-quality, life-changing healthcare innovations to meet medical needs through scientific excellence and establish a risk-to-growth balance acceptable to the business. I see strong momentum in our business areas with great promise for the future. In the quarter, we saw sales equal to the previous year same quarter. The gross margin at 91% (88%) indicates underlying stability while absorbing cost increases in the supply chain. Our EBITDA margin was 21% (12%), a very pleasing result for the start of the year”, said Justin Pierce, CEO of Magle Chemoswed Holding.